{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T17:40:03Z","timestamp":1754070003788,"version":"3.41.2"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:sec>\n            <jats:title>Background and aims<\/jats:title>\n            <jats:p>Primary biliary cholangitis (PBC) is an immune-mediated liver disease. The immunological profile seems to relate to clinical prognosis. This study aims to determine the role of autoantibodies in the course of liver disease and in the response to ursodeoxycholic acid.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Between January 2016 and December 2020, 143 patients with PBC who underwent immunological liver profile evaluation were enrolled. All data were extracted retrospectively from electronic clinical records. Chi-square test, Fisher\u2019s exact test and Mann\u2013Whitney test were used to evaluate the relationship between autoantibodies and biochemical parameters, clinical outcomes and therapeutic response scores. A significance level of 0.05 was used.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Antimitochondrial antibodies were present in 91.6%, antiglycoprotein-210 antibody (anti-gp210) in 18.2% and anti-Sp100 in 19.6% of patients. The incidence of liver-related death was higher in patients with autoimmune hepatitis variants. The occurrence of cirrhosis or portal hypertension was not linked to the presence of any of the autoantibodies tested. No relationship was found with the probability of dying or being transplanted. Patients with anti-Sp100 antibodies had higher baseline levels of aspartate aminotransferase and alanine aminotransferase and lower immunoglobulin M levels. Patients with anti-gp210 were more likely to have a lower median transplant-free survival rate and higher median risk of liver transplant or liver-related death using the GLOBE and UK-PBC scores.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Our findings confirm a strong association between anti-gp210 antibodies and a worse outcome. The association between anti-Sp100 and hepatic lesions requires further elucidation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/meg.0000000000002565","type":"journal-article","created":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T14:35:51Z","timestamp":1682692551000},"page":"682-689","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Correlation between individual autoantibodies and clinical features in primary biliary cholangitis: results of a retrospective longitudinal study"],"prefix":"10.1097","volume":"35","author":[{"given":"Beatriz","family":"Dias","sequence":"first","affiliation":[{"name":"Instituto de Ci\u00eancias Biom\u00e9dicas de Abel Salazar"}]},{"given":"Ana","family":"Aguiar","sequence":"additional","affiliation":[{"name":"Instituto de Ci\u00eancias Biom\u00e9dicas de Abel Salazar"},{"name":"EPIUnit - Instituto De Sa\u00fade P\u00fablica, Universidade do Porto"},{"name":"Laborat\u00f3rio para a Investiga\u00e7\u00e3o Integrativa e Translacional em Sa\u00fade Populacional (ITR)"}]},{"given":"C\u00e1tia Iracema","family":"Morais","sequence":"additional","affiliation":[{"name":"Instituto de Ci\u00eancias Biom\u00e9dicas de Abel Salazar"},{"name":"Servi\u00e7o de Imunologia, Departamento de Patologia, Centro Hospitalar e Universit\u00e1rio de Santo Ant\u00f3nio"}]},{"given":"Filipe Gaio","family":"Nery","sequence":"additional","affiliation":[{"name":"Instituto de Ci\u00eancias Biom\u00e9dicas de Abel Salazar"},{"name":"EPIUnit - Instituto De Sa\u00fade P\u00fablica, Universidade do Porto"},{"name":"Laborat\u00f3rio para a Investiga\u00e7\u00e3o Integrativa e Translacional em Sa\u00fade Populacional (ITR)"},{"name":"Unidade de Cuidados Interm\u00e9dios M\u00e9dicos, Servi\u00e7o de Cuidados Intensivos, Centro Hospitalar e Universit\u00e1rio de Santo Ant\u00f3nio, Porto, Portugal"}]}],"member":"276","published-online":{"date-parts":[[2023,4,15]]},"reference":[{"key":"R1-20250801","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.jhep.2015.06.031","article-title":"Changing nomenclature for PBC: from \u2018cirrhosis\u2019 to \u2018cholangitis\u2019.","volume":"63","author":"Beuers","year":"2015","journal-title":"J Hepatol"},{"key":"R2-20250801","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis.","volume":"67","author":"Hirschfield","year":"2017","journal-title":"J Hepatol"},{"key":"R3-20250801","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/hep.22906","article-title":"Primary biliary cirrhosis.","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"key":"R4-20250801","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s00281-009-0164-5","article-title":"Primary biliary cirrhosis.","volume":"31","author":"Hohenester","year":"2009","journal-title":"Semin Immunopathol"},{"key":"R5-20250801","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1055\/s-2005-916321","article-title":"Antinuclear antibodies in primary biliary cirrhosis.","volume":"25","author":"Invernizzi","year":"2005","journal-title":"Semin Liver Dis"},{"key":"R6-20250801","doi-asserted-by":"crossref","first-page":"034","DOI":"10.1055\/s-0039-1697617","article-title":"The pathogenesis of primary biliary cholangitis: a comprehensive review.","volume":"40","author":"Lleo","year":"2020","journal-title":"Semin Liver Dis"},{"key":"R7-20250801","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/hep.21172","article-title":"Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis.","volume":"43","author":"Wesierska-Gadek","year":"2006","journal-title":"Hepatology"},{"key":"R8-20250801","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1080\/08916930802709133","article-title":"Multiple nuclear dots and rim-like\/membranous IgG isotypes in primary biliary cirrhosis.","volume":"42","author":"Muratori","year":"2009","journal-title":"Autoimmunity"},{"key":"R9-20250801","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1586\/erm.11.82","article-title":"Antinuclear antibodies as ancillary markers in primary biliary cirrhosis.","volume":"12","author":"Granito","year":"2012","journal-title":"Expert Rev Mol Diagn"},{"key":"R10-20250801","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1111\/j.1365-2036.2006.03172.x","article-title":"Antinuclear antibodies giving the \u2018multiple nuclear dots\u2019 or the \u2018rim-like\/membranous\u2019 patterns: diagnostic accuracy for primary biliary cirrhosis.","volume":"24","author":"Granito","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"R11-20250801","first-page":"1","article-title":"Early prognostic utility of Gp210 antibody-positive rate in primary biliary cholangitis: a meta-analysis.","volume":"2019","author":"Huang","year":"2019","journal-title":"Dis Markers"},{"key":"R12-20250801","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/liv.14688","article-title":"Antibodies to gp210 and understanding risk in patients with primary biliary cholangitis.","volume":"41","author":"Haldar","year":"2021","journal-title":"Liver Int"},{"key":"R13-20250801","first-page":"S1590-8658(21)00816-1","article-title":"The prognostic value of antibodies to gp210 among patients with primary biliary cholangitis in Northeast China.","volume":"54","author":"Chen","year":"2021","journal-title":"Dig Liver Dis"},{"key":"R14-20250801","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/hep.21472","article-title":"Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis.","volume":"45","author":"Nakamura","year":"2007","journal-title":"Hepatology"},{"key":"R15-20250801","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2169\/internalmedicine.50.4462","article-title":"Risk factors and prediction of long-term outcome in primary biliary cirrhosis.","volume":"50","author":"Ishibashi","year":"2011","journal-title":"Intern Med"},{"issue":"s3","key":"R16-20250801","doi-asserted-by":"crossref","first-page":"S412","DOI":"10.1111\/j.1872-034X.2007.00244.x","article-title":"Predictive role of anti-gp210 and anticentromere antibodies in long-term outcome of primary biliary cirrhosis.","volume":"37","author":"Nakamura","year":"2007","journal-title":"Hepatol Res"},{"key":"R17-20250801","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/liv.12690","article-title":"Anti-kelch-like 12 and anti-hexokinase 1: novel autoantibodies in primary biliary cirrhosis.","volume":"35","author":"Norman","year":"2015","journal-title":"Liver Int"},{"key":"R18-20250801","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.14309\/ajg.0000000000000690","article-title":"Novel anti\u2013hexokinase 1 antibodies are associated with poor prognosis in patients with primary biliary cholangitis.","volume":"115","author":"Reig","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"R19-20250801","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/hep.510280203","article-title":"Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy: primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy.","volume":"28","author":"Chazouill\u00e8res","year":"1998","journal-title":"Hepatology"},{"key":"R20-20250801","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jhep.2016.12.022","article-title":"Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis.","volume":"66","author":"Karlas","year":"2017","journal-title":"J Hepatol"},{"key":"R21-20250801","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/hep.25599","article-title":"Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis.","volume":"56","author":"Corpechot","year":"2012","journal-title":"Hepatology"},{"key":"R22-20250801","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","article-title":"Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy.","volume":"149","author":"Lammers","year":"2015","journal-title":"Gastroenterology"},{"key":"R23-20250801","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/hep.28017","article-title":"The UK-PBC risk scores: derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis.","volume":"63","author":"Carbone","year":"2016","journal-title":"Hepatology"},{"key":"R24-20250801","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid.","volume":"130","author":"Par\u00e9s","year":"2006","journal-title":"Gastroenterology"},{"key":"R25-20250801","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","article-title":"Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.","volume":"48","author":"Corpechot","year":"2008","journal-title":"Hepatology"},{"key":"R26-20250801","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1053\/j.gastro.2009.01.003","article-title":"Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.","volume":"136","author":"Kuiper","year":"2009","journal-title":"Gastroenterology"},{"key":"R27-20250801","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","article-title":"Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome.","volume":"55","author":"Corpechot","year":"2011","journal-title":"J Hepatol"},{"key":"R28-20250801","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1478-3231.2011.02678.x","article-title":"Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis.","volume":"32","author":"Momah","year":"2012","journal-title":"Liver Int"},{"issue":"Suppl 2","key":"R29-20250801","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000440705","article-title":"Worldwide incidence of autoimmune liver disease.","volume":"33","author":"Jepsen","year":"2015","journal-title":"Dig Dis"},{"key":"R30-20250801","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/ueg2.12095","article-title":"Predictors for incomplete response to ursodeoxycholic acid in primary biliary cholangitis. Data from a national registry of liver disease.","volume":"9","author":"Cortez-Pinto","year":"2021","journal-title":"United European Gastroenterol J"},{"key":"R31-20250801","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1053\/gast.2002.36027","article-title":"Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years.","volume":"123","author":"Prince","year":"2002","journal-title":"Gastroenterology"},{"key":"R32-20250801","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.bpg.2018.05.013","article-title":"PBC and related extrahepatic diseases.","volume":"34-35","author":"Floreani","year":"2018","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"R33-20250801","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/jgh.15214","article-title":"Extrahepatic autoimmune diseases in primary biliary cholangitis: prevalence and significance for clinical presentation and disease outcome.","volume":"36","author":"Efe","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"key":"R34-20250801","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/hep.510280210","article-title":"Frequency and nature of the variant syndromes of autoimmune liver disease.","volume":"28","author":"Czaja","year":"1998","journal-title":"Hepatology"},{"key":"R35-20250801","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.cgh.2011.03.019","article-title":"Prevalence of primary biliary cirrhosis\u2013autoimmune hepatitis overlap syndrome.","volume":"9","author":"Bonder","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R36-20250801","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s12016-015-8516-5","article-title":"The natural history and prognosis of primary biliary cirrhosis with clinical features of autoimmune hepatitis.","volume":"50","author":"Yang","year":"2016","journal-title":"Clin Rev Allerg Immunol"},{"key":"R37-20250801","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1111\/j.1572-0241.2007.01136.x","article-title":"Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes.","volume":"102","author":"Silveira","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"R38-20250801","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3109\/08916934.2013.801461","article-title":"Clinical significance of the fluctuation of primary biliary cirrhosis-related autoantibodies during the course of the disease.","volume":"46","author":"Gatselis","year":"2013","journal-title":"Autoimmunity"},{"key":"R39-20250801","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jhep.2004.11.016","article-title":"Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis.","volume":"42","author":"Nakamura","year":"2005","journal-title":"J Hepatol"},{"key":"R40-20250801","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/apt.13927","article-title":"The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210.","volume":"45","author":"Yang","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"R41-20250801","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1440-1746.1998.01553.x","article-title":"Autoantibodies against a 210kDa glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis.","volume":"13","author":"Itoh","year":"1998","journal-title":"J Gastroenterol Hepatol"},{"key":"R42-20250801","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1136\/gut.2003.036558","article-title":"Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis.","volume":"54","author":"Rigopoulou","year":"2005","journal-title":"Gut"},{"key":"R43-20250801","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1055\/s-0034-1383732","article-title":"Clinical significance of autoantibodies in primary biliary cirrhosis.","volume":"34","author":"Nakamura","year":"2014","journal-title":"Semin Liver Dis"},{"key":"R44-20250801","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.cca.2012.03.020","article-title":"Diagnostic and clinical utility of antibodies against the nuclear body promyelocytic leukaemia and Sp100 antigens in patients with primary biliary cirrhosis.","volume":"413","author":"Mytilinaiou","year":"2012","journal-title":"Clin Chim Acta"}],"container-title":["European Journal of Gastroenterology &amp; Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MEG.0000000000002565","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T17:03:37Z","timestamp":1754067817000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MEG.0000000000002565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,15]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/meg.0000000000002565","relation":{},"ISSN":["0954-691X"],"issn-type":[{"type":"print","value":"0954-691X"}],"subject":[],"published":{"date-parts":[[2023,4,15]]}}}